Food for thought: addressing undernutrition to end tuberculosis
P Sinha, K Lönnroth, A Bhargava… - The Lancet Infectious …, 2021 - thelancet.com
Tuberculosis is the leading cause of deaths from an infectious disease worldwide. WHO's
End TB Strategy is falling short of several 2020 targets. Undernutrition is the leading …
End TB Strategy is falling short of several 2020 targets. Undernutrition is the leading …
New old challenges in tuberculosis: potentially effective nanotechnologies in drug delivery
A Sosnik, ÁM Carcaboso, RJ Glisoni… - Advanced drug delivery …, 2010 - Elsevier
Tuberculosis (TB) is the second most deadly infectious disease. Despite potentially curative
pharmacotherapies being available for over 50years, the length of the treatment and the pill …
pharmacotherapies being available for over 50years, the length of the treatment and the pill …
Efficacy and safety of high-dose rifampin in pulmonary tuberculosis. A randomized controlled trial
GE Velásquez, MB Brooks, JM Coit… - American journal of …, 2018 - atsjournals.org
Rationale: We examined whether increased rifampin doses could shorten standard therapy
for tuberculosis without increased toxicity. Objectives: To assess the differences across three …
for tuberculosis without increased toxicity. Objectives: To assess the differences across three …
Clinical pharmacokinetics and pharmacodynamics of rifampicin in human tuberculosis
The introduction of rifampicin (rifampin) into tuberculosis (TB) treatment five decades ago
was critical for shortening the treatment duration for patients with pulmonary TB to 6 months …
was critical for shortening the treatment duration for patients with pulmonary TB to 6 months …
Microbiome-immune interactions in tuberculosis
Tuberculosis (TB) remains an infectious disease of global significance and a leading cause
of death in low-and middle-income countries. Significant effort has been directed towards …
of death in low-and middle-income countries. Significant effort has been directed towards …
Rifampicin and rifapentine significantly reduce concentrations of bedaquiline, a new anti-TB drug
EM Svensson, S Murray, MO Karlsson… - Journal of …, 2015 - academic.oup.com
Objectives Bedaquiline is the first drug of a new class approved for the treatment of TB in
decades. Bedaquiline is metabolized by cytochrome P450 (CYP) 3A4 to a less-active M2 …
decades. Bedaquiline is metabolized by cytochrome P450 (CYP) 3A4 to a less-active M2 …
Effects of Tuberculosis, Race, and Human Gene SLCO1B1 Polymorphisms on Rifampin Concentrations
Rifampin has concentration-dependent activity against Mycobacterium tuberculosis.
However, marked intersubject variation of rifampin concentrations occurs. In this study, we …
However, marked intersubject variation of rifampin concentrations occurs. In this study, we …
Pharmacokinetics of isoniazid, rifampin, and pyrazinamide in children younger than two years of age with tuberculosis: evidence for implementation of revised World …
ABSTRACT The World Health Organization (WHO) recently issued revised first-line
antituberculosis (anti-TB) drug dosage recommendations for children. No pharmacokinetic …
antituberculosis (anti-TB) drug dosage recommendations for children. No pharmacokinetic …
[HTML][HTML] The effect of undernutrition on sputum culture conversion and treatment outcomes among people with multidrug-resistant tuberculosis: a systematic review …
Objectives We aimed to evaluate the effect of undernutrition on sputum culture conversion
and treatment outcomes among people with multidrug-resistant tuberculosis (MDR-TB) …
and treatment outcomes among people with multidrug-resistant tuberculosis (MDR-TB) …
[HTML][HTML] Tuberculosis of the gastrointestinal tract and associated viscera
Tuberculosis involvement of the gastrointestinal tract, peritoneum, and associated viscera is
an uncommon but well described entity. While peritoneal tuberculosis and tuberculous …
an uncommon but well described entity. While peritoneal tuberculosis and tuberculous …